Skip to main content

Biofortuna to Further Commercialize Genotyping Assays With £1.6M Financing

NEW YORK (GenomeWeb) – Biofortuna today announced it has raised £1.6 million ($2.1 million) to support taking its genotyping assays into clinical trials and commercialization.

Investors in the new funding round included current investor venture capital firm Foresight and members of Biofortuna's senior management team. The company said that the funds will be used to take its ReadyPlex rapid blood group genotyping assays further toward commercialization, and allow Biofortuna to invest in additional resources in its contract manufacturing infrastructure.

ReadyPlex is based on PCR technology for the genomic analysis of blood groups, platelet antigens, neutrophil antigens, and coagulation polymorphisms. Biofortuna said that in addition to launching ReadyPlex products, it will invest in its freeze-drying production, and dispensing and packaging capabilities.

In January, the UK firm announced a new investment into its IVD service portfolio, allowing it to greater focus on immunoassay design, development, and manufacturing. The company also raised £1.5 million in early 2015.